BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Unicyte

Top Companies Developing Cell Therapy Treatments For Diabetes

December 19, 2021 By Cade Hildreth (CEO) 5 Comments

Below is a list of the top companies exploring cell therapy treatments for diabetes.

In this article:

  • Companies Exploring Stem Cell Treatment for Diabetes
    1. Seraxis | Cell Replacement Therapy for Type 1 Diabetes
    2. Unicyte AG | Diabetes Cell Therapy
    3. ViaCyte | Insulin for Diabetes
    4. Sernova | Stem Cell for Diabetes Treatment
    5. Betalin Therapeutics | Insulin Production
    6. AltuCell | Stem Cell Therapy for Diabetes Type 2
    7. NextCell Pharma AB | Stem Cell Therapy for Diabetes Type 1
    8. Osiris Therapeutics | Type 1 Diabetes Control
    9. Mesoblast | Type 2 Diabetes Treatment
    10. Evotec and Sanofi | Stem Cell for Diabetes
    11. Orgenesis | Insulin-Producing Cells
    12. Semma Therapeutics | Type 1 Diabetes Therapy
    13. Novo Nordisk | Treatment of Type 1 Diabetes
    14. Beta-O2 | Artificial Pancreas for Diabetes
    15. Eli Lilly and Sigilon | Stem Cell for Diabetes
    16. Pharmacyte Biotech | Encapsulated Human Cells

[Read more…]

Filed Under: Stem Cells Tagged With: Altucell, diabetes, Seraxis, Sernova, Unicyte, ViaCyte

Unicyte and Collaboration Partner Prof. Camussi Achieve Preclinical Milestone in Diabetes Program

September 18, 2018 By Cade Hildreth (CEO) Leave a Comment

Unicyte, a regenerative medicine unit of Fresenius Medical Care, and its collaboration partner Professor Camussi have published results in Stem Cell Reviews and Reports that a potential therapeutic strategy for diabetes is the transplantation of induced-insulin secreting cells.

The Global Disease Burden of Diabetes Mellitus

Diabetes mellitus is one of the most common diseases globally. Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period. With an aging population and surging rates of obesity, the incidence of this debilitating disease on the rise. [Read more…]

Filed Under: Cell Therapy, Stem Cell News Tagged With: diabetes, Unicyte

Fresenius Medical Care achieves preclinical milestone in its regenerative medicine program for chronic kidney disease

July 30, 2018 By Cade Hildreth (CEO) Leave a Comment

Unicyte_nEV_Fibrosis

Unicyte

July 30, 2018 – Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that its subsidiary Unicyte AG has achieved a key preclinical milestone in its regenerative medicine program for chronic kidney disease. The company was able to confirm a disease modifying potential for its proprietary nano-Extracellular Vesicles (“nEVs” are stem cell-derived particles that support communication between cells) in a second preclinical model of chronic kidney disease. [Read more…]

Filed Under: Press Releases Tagged With: Fresenius Medical Care, Unicyte

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.